Korea’s First GLP-1 Obesity Drug Fast-Tracked: Hanmi’s “Efpeglenatide” Signals Acceleration in Biotech Commercialization - KoreaTechDesk | Korean Startup and Technology News Hanmi’s Efpeglenatide earns fast-track review in Korea, marking a breakthrough in biotech commercialization and homegrown GLP-1 drug innovation.

💥 Korea’s first GLP-1 obesity drug is racing to market! 💊

Hanmi’s Efpeglenatide just got fast-tracked for approval — marking a turning point in Korean biotech innovation.

🔗 Full story: koreatechdesk.com/koreas-first...
#HanmiPharma #GLP1 #Biotech #KoreanInnovation #KoreaTechDesk